

## Evaluation of HAAs as a Class or Subclass(es)



**Stan Atwood, MS, DABT**

Integrated Laboratory Systems, Inc.

Contractor supporting the Office of the Report on Carcinogens

National Institute of Environmental Health Sciences

July 24, 2017



# HAAs as a Class or Subclass(es)

## Outline

Class

- All 13 HAAs as a potential class

Subclasses

- 7 Potential subclasses

Analogues  
(metabolism)

- Individual untested HAAs (carcinogenicity)



# Can all 13 HAAs be Considered a Class?

---

## Approach and methods

- Conduct read across-like analysis
  - Informed by previous sections of the monograph
  - Compared potency values for biological effects
- Evaluate published QSARs for biological effects
- Evaluate QSAR modeling to predict carcinogenicity



# Conduct Read-Across Analysis

## Biological effects varied with number and type of halogens

Endpoint	Mono-HAAs	Di-HAAs	Tri-HAAs
Properties (reactivity)	Electrophilicity ( $E_{LUMO}$ ), pKa		
Metabolism & Toxicokinetics	Comparative data		
Mechanistic data	Comparative data: potency		
Animal cancer data	Br-HAAs more cancer sites than Cl-HAAs TD <sub>50</sub> and BMDLs for quantitative assessment		

- Potency of biological effects increased (*in vitro*)\*
  - with decreasing number of halogens
  - with increasing halogen size
- these trends are related to chemical properties
- Limitations/challenges
  - no well defined mechanism for HAA carcinogenicity
  - cancer potency metric

\* Graphical representation (Table 7-1) in the Monograph captures all data evaluated



## Published QSAR models successfully predicted effects related to the characteristics of carcinogens

- Predicted potency for **oxidative stress** and **genetic damage** in cultured mammalian cells for 12 HAAs
- Predicted potency of **neural tube defects** in mouse embryo cultures (*ex vivo*) for 10 HAAs
- These models were based on pKa and  $E_{LUMO}$ 
  - pKa relates to bioavailability/transport
  - $E_{LUMO}$  relates to intrinsic activity/covalent interaction with macromolecules



## Published QSAR models successfully predicted effects related to the characteristics of carcinogens

- Predicted potency for **oxidative stress** and **genetic damage** in cultured mammalian cells for 12 HAAs
- Predicted potency of **neural tube defects** in mouse embryo cultures (*ex vivo*) for 10 HAAs
- These models were based on pKa and  $E_{LUMO}$ 
  - pKa relates to bioavailability/transport
  - $E_{LUMO}$  relates to intrinsic activity/covalent interaction with macromolecules

Could we develop a similar QSAR model to predict carcinogenicity?



# Evaluate QSAR Modeling for Carcinogenicity


---

## QSAR approach failed to predict animal carcinogenicity

- Empirical animal data results
  - Br-HAAs were associated with more cancer sites than Cl-HAAs
  - MCA was not carcinogenic
- Modeled cancer potency estimates did not show the expected trends
  - Published Benchmark Dose Low (BMDL, mg/kg/day)
  - Predicted Toxic Dose 50 (TD<sub>50</sub>, mg/kg/day)
    - MCA was predicted to be carcinogenic



## Outline







# Evaluate Seven Potential Subclasses

## Approach and Methods

- Same general approach as with all 13 HAAs
- Considered 7 smaller groups based on number and type of halogens
  - Subclasses include tested and non-tested chemicals for animal carcinogenicity
  - Evaluate the confidence for read across
    - Are there testing data for at least one member of the subclass?
    - Are there testing data for HAAs containing the principal halogen(s) within the subclass?
    - Does the subclass contain any HAAs tested in animals and found not to cause tumors?
    - Are there other similarity criteria (e.g., metabolism, chemical, biological)?



# Conduct Read-Across Analysis for Subclasses

Data were insufficient to support read across for subclasses

Subclass	Members*	Confidence as a potential category for read across
Mono-HAAs	MCA, MBA, MIA	No
Di-HAAs	DCA, DBA, BCA, DIA, CIA, BIA	Low
Tri-HAAs	TCA, BDCA, CDBA, TBA	Low
CI-HAAs	MCA, DCA, BCA, CIA, TCA	No
Br-HAAs	BA, DBA, BCA, BIA, TBA, BDCA, CDBA	Low/moderate
I-HAAs	IA, DIA, CIA, BIA	No
Br-Di-/Tri-HAAs	DBA, BCA, BIA, BDCA, CDBA, TBA	Moderate

\* Red = rodent carcinogens, blue = not carcinogenic, black = no animal carcinogenicity data



# Brominated-Di/Tri-HAAs Subclass

## Example evaluation

Subclass	Members*	Confidence as a potential category for read across
Br-Di-/Tri-HAAs	DBA, BCA, BIA, BDCA, CDBA, TBA	Moderate


- Testing data for 3 members: DBA, BCA, BDCA
- No testing data for any iodinated HAAs
- CDBA and TBA are metabolized to tested HAAs
- Two untested chemicals (CDBA, TBA) have similar properties as tested chemical (BDCA)

Conclusion: Read across to BIA is too uncertain without a defined mechanism of action and/or animal carcinogenicity data for an iodinated HAA.



# Evaluate Individual Untested Chemicals

## Outline





# Evaluate Individual Untested HAAs

---

## Subclass evaluation informed potential “read-across” for two tri-HAAs without cancer data (CDBA and TBA)

- Metabolism data and analogue approach
- Metabolites and analogues are known animal carcinogens
- Supporting mechanistic data



# Tri-HAAs Metabolized to Di-HAAs

- Tri-HAAs with both Cl and Br always lose a Br
- Br loss from Tri-HAA corresponds 1:1 to Di-HAA formation
- Br substitution for Cl enhances metabolism
- TBA and CDBA: no animal cancer data but are metabolized to animal carcinogens
- No other microsomal metabolites identified

No. of Bromines	Parent	Relative extent of metabolism	Metabolite
0	TCA	→	DCA
1	BDCA	→	DCA
2	CDBA	→	BCA
3	TBA	→	DBA



# All Tested Br-HAAs are Rodent Carcinogens

Species/ Tumor type	Tested chemicals			Untested chemicals	
	BCA	DBA	BDCA	CDBA	TBA
<b>Rats</b>	✓	✓	✓		
MCL	–	✓	–		
Mesothelioma	✓	✓	✓		
Mammary	✓	–	✓		
Skin	–	–	✓		
<b>Mice</b>	✓	✓	✓		
Liver	✓	✓	✓		
Lung	–	✓	–		
Harderian gland	–	–	✓		

✓ = tumor site, – = not a tumor site



## CDBA and TBA are metabolized to rodent carcinogens

Species/ Tumor type	Tested chemicals			Untested chemicals	
	BCA	DBA	BDCA	CDBA	TBA
<b>Rats</b>	✓	✓	✓		
MCL	–	✓	–		
Mesothelioma	✓	✓	✓		
Mammary	✓	–	✓		
Skin	–	–	✓		
<b>Mice</b>	✓	✓	✓		
Liver	✓	✓	✓		
Lung	–	✓	–		
Harderian gland	–	–	✓		

✓ = tumor site, – = not a tumor site





# Other Supporting Data

## CDBA and TBA are similar (properties/effects) to BDCA

Species/ Tumor type	Tested chemicals			Untested chemicals	
	BCA	DBA	BDCA	CDBA	TBA
<b>Rats</b>	✓	✓	✓		
MCL	–	✓	–		
Mesothelioma	✓	✓	✓		
Mammary	✓	–	✓		
Skin	–	–	✓		
<b>Mice</b>	✓	✓	✓		
Liver	✓	✓	✓		
Lung	–	✓	–		
Harderian gland	–	–	✓		

✓ = tumor site, – = not a tumor site



## CDBA and TBA are predicted to be rodent carcinogens

Species/ Tumor type	Tested chemicals			Untested chemicals	
	BCA	DBA	BDCA	CDBA	TBA
<b>Rats</b>	✓	✓	✓	Predicted	Predicted
MCL	–	✓	–		
Mesothelioma	✓	✓	✓	Likely site	Likely site
Mammary	✓	–	✓		
Skin	–	–	✓		
<b>Mice</b>	✓	✓	✓	Predicted	Predicted
Liver	✓	✓	✓	Very likely site	Very likely site
Lung	–	✓	–		
Harderian gland	–	–	✓		

✓ = tumor site, – = not a tumor site



- CDBA and TBA have chemical properties and biological effects similar to that of BDCA that caused cancer in experimental animals
  - Electrophiles
  - Oxidative stress
  - DNA damage
- These properties and effects are relevant to humans



# HAAs as a Class or Subclass(es)

## Summary

Class

- All 13 HAAs as a potential class: **No**

Subclasses

- 7 Potential subclasses: **No**


Analogues  
(metabolism)

- Individual untested HAAs (carcinogenicity):  
**Yes**



# HAAAs as a Class or Subclass(es)

**Questions?**





## Reviewer Questions

- Comment on the methods and approaches for evaluating haloacetic acids as a class or subclass.
- Comment on the assessment and NTP's conclusion that the available data are inadequate to evaluate haloacetic acids as a class.
- Comment on the assessment and NTP's conclusion that the available data are inadequate to evaluate haloacetic acids as a subclass or subclasses (based on number or type of halogen substitutions).
- Comment on the assessment and NTP's conclusion that metabolism data and read across principles can be applied to two haloacetic acids (CDBA and TBA) without cancer data.